Pre-emptive treatment helped curtail skin toxicity with panitumumab

Jan 16, 2009

With a pre-emptive, prophylactic skin regimen, patients who receive panitumumab for treatment of metastatic colorectal cancer may be able to avoid some of the skin-associated toxicities, according to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study, which was the first prospective study to compare pre-emptive and reactive skin treatment for skin toxicities related to panitumumab. The study was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University's Feinberg School of Medicine in Chicago.

Skin toxicities are the most common adverse effects related to panitumumab, which is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The toxicities could include erythema, dermatitis, pruritus, pustules, rash, and hair and nail changes.

"Panitumumab and the other EGFR inhibitors are now key components to the treatment strategies for metastatic colorectal cancer," Dr. Mitchell said. "But the majority of the patients who receive these agents suffer from skin toxicities, and for some patients, the treatment must be interrupted or discontinued. If we can prevent or minimize these toxicities, it would be a significant advance in patient care."

The researchers studied 95 patients receiving panitumumab in combination with irinotecan-based chemotherapy. The patients were randomized to receive pre-emptive skin toxicity treatment initiated 24 hours prior to the first dose of panitumumab, then given daily through week six, or reactive skin treatment after the skin toxicity developed. The skin treatment included moisturizers, sunscreen, topical steroids and oral doxycycline.

The primary endpoint was the incidence of specific grade 2 or higher skin toxicities during the six week skin treatment period. The incidence of these toxicities was reduced more than 50% in the group that received pre-emptive treatment.

Quality of life was also assessed, using the Dermatology Life Quality Index. Patients who received the pre-emptive, prophylactic skin treatment regimen reported an improved quality of life, even around week three, which was the median time to first grade 2 or higher skin toxicity in the reactive skin treatment group.

Source: Thomas Jefferson University

Explore further: Patient, tumor characteristics for high-mitotic rate melanoma

add to favorites email to friend print save as pdf

Related Stories

UMSL scholar examines evolution of learning

1 hour ago

Why do monkeys learn to be afraid of snakes and not flowers? Is this knowledge the result of evolution by natural selection? Did the monkeys that couldn't learn that association quickly die and not reproduce?

Study details shortage of replication in education research

1 hour ago

Although replicating important findings is essential for helping education research improve its usefulness to policymakers and practitioners, less than one percent of the articles published in the top education research journals ...

Samsung introduces Galaxy Alpha

1 hour ago

Samsung Electronics unveiled its new design approach with the Galaxy Alpha. The latest addition to Samsung's Galaxy smartphone line, the Galaxy Alpha features a sophisticated design in a carefully constructed ...

People fake to look authentic on social media

2 hours ago

Presenting an authentic image on social network sites (SNSs) includes an element of fakery according to a new study by researchers at Aalto University. During the study, researchers discovered that being authentic is very ...

Recommended for you

User comments : 0